Atezolizumab-tiragolumab for locally advanced, recurrent, or metastatic PD-L1 selected solid tumours

Atezolizumab-tiragolumab is currently in clinical development for treating adults with Programmed death ligand 1 (PD-L1)-selected solid tumours whose disease is locally advanced, recurrent or metastatic. Cancer is a condition where cells in a specific part of the body grow and reproduce uncontrollably. These cancerous cells can invade and destroy healthy tissue, including organs. One in every two people will develop cancer in their lifetime. PD-1 is a protein that normally acts as an “off switch,” helping to stop immune cells from attacking other cells in the body. It does this by attaching to PD-L1, a protein found on some normal (and cancer) cells. PD-L1-select tumours have high amounts of PD-L1 so they can turn T cells off so they can’t attack the cancer cells. This allows cancer cells to evade immune attack.